These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26954848)

  • 21. Simultaneous activation of the α1A-, α1B- and α1D-adrenoceptor subtypes in the nucleus accumbens reduces accumbal dopamine efflux in freely moving rats.
    Aono Y; Taguchi H; Saigusa T; Uchida T; Takada K; Takiguchi H; Shirakawa T; Shimizu N; Koshikawa N; Cools AR
    Behav Pharmacol; 2015 Feb; 26(1-2):73-80. PubMed ID: 25438092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chiral analogues of (+)-cyclazosin as potent α
    Sagratini G; Buccioni M; Marucci G; Poggesi E; Skorski M; Costanzi S; Giardinà D
    Bioorg Med Chem; 2018 Jul; 26(12):3502-3513. PubMed ID: 29784274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and Pharmacological Evaluation of Novel Silodosin-Based Arylsulfonamide Derivatives as α
    Canale V; Rak A; Kotańska M; Knutelska J; Siwek A; Bednarski M; Nowiński L; Zygmunt M; Koczurkiewicz P; Pękala E; Sapa J; Zajdel P
    Molecules; 2018 Aug; 23(9):. PubMed ID: 30158432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological and electrophysiological characterization of AZSMO-23, an activator of the hERG K(+) channel.
    Mannikko R; Bridgland-Taylor MH; Pye H; Swallow S; Abi-Gerges N; Morton MJ; Pollard CE
    Br J Pharmacol; 2015 Jun; 172(12):3112-25. PubMed ID: 25684549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis, crystal structure, biological evaluation and molecular docking studies of carbazole-arylpiperazine derivatives.
    Xu W; Huang J; Shao B; Xu X; Jiang R; Yuan M
    Bioorg Med Chem; 2016 Nov; 24(21):5565-5572. PubMed ID: 27663545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
    Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
    J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of molecular modeling aided design to dial out hERG liability in adenosine A(2A) receptor antagonists.
    Deng Q; Lim YH; Anand R; Yu Y; Kim JH; Zhou W; Zheng J; Tempest P; Levorse D; Zhang X; Greene S; Mullins D; Culberson C; Sherborne B; Parker EM; Stamford A; Ali A
    Bioorg Med Chem Lett; 2015 Aug; 25(15):2958-62. PubMed ID: 26048804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimization of a series of 2,4-diaminopyridines as neuropeptide Y Y1 receptor antagonists with reduced hERG activity.
    Kameda M; Kobayashi K; Ito H; Miyazoe H; Tsujino T; Nakama C; Kawamoto H; Ando M; Ito S; Suzuki T; Kanno T; Tanaka T; Tahara Y; Tani T; Tanaka S; Tokita S; Sato N
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4325-9. PubMed ID: 19487123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using electrophysiology and in silico three-dimensional modeling to reduce human Ether-à-go-go related gene K(+) channel inhibition in a histamine H3 receptor antagonist program.
    Davenport AJ; Möller C; Heifetz A; Mazanetz MP; Law RJ; Ebneth A; Gemkow MJ
    Assay Drug Dev Technol; 2010 Dec; 8(6):781-9. PubMed ID: 21133680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis.
    Cumming JG; Tucker H; Oldfield J; Fielding C; Highton A; Faull A; Wild M; Brown D; Wells S; Shaw J
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1655-9. PubMed ID: 22266038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.
    Berglund S; Egner BJ; Gradén H; Gradén J; Morgan DG; Inghardt T; Giordanetto F
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4274-9. PubMed ID: 19500982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the ion works HTTM system.
    Guthrie H; Livingston FS; Gubler U; Garippa R
    J Biomol Screen; 2005 Dec; 10(8):832-40. PubMed ID: 16234341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 1H-Pyrazolo[3,4-g]hexahydro-isoquinolines as potent GR antagonists with reduced hERG inhibition and an improved pharmacokinetic profile.
    Hunt HJ; Belanoff JK; Golding E; Gourdet B; Phillips T; Swift D; Thomas J; Unitt JF; Walters I
    Bioorg Med Chem Lett; 2015 Dec; 25(24):5720-5. PubMed ID: 26546213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological analysis of the novel, selective alpha1-adrenoceptor antagonist, KMD-3213, and its suitability as a tritiated radioligand.
    Murata S; Taniguchi T; Muramatsu I
    Br J Pharmacol; 1999 May; 127(1):19-26. PubMed ID: 10369451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Function of the lower urinary tract in mice lacking alpha1d-adrenoceptor.
    Chen Q; Takahashi S; Zhong S; Hosoda C; Zheng HY; Ogushi T; Fujimura T; Ohta N; Tanoue A; Tsujimoto G; Kitamura T
    J Urol; 2005 Jul; 174(1):370-4. PubMed ID: 15947692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and evaluation of an in silico model for hERG binding.
    Song M; Clark M
    J Chem Inf Model; 2006; 46(1):392-400. PubMed ID: 16426073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.
    Gillespie JI; Palea S; Guilloteau V; Guerard M; Lluel P; Korstanje C
    BJU Int; 2012 Jul; 110(2 Pt 2):E132-42. PubMed ID: 22734512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of silodosin on detrusor overactivity in the male spontaneously hypertensive rat.
    Inoue S; Saito M; Tsounapi P; Dimitriadis F; Ohmasa F; Kinoshita Y; Satoh K; Takenaka A
    BJU Int; 2012 Jul; 110(2 Pt 2):E118-24. PubMed ID: 22146017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of naftopidil, an alpha1D/A-adrenoceptor antagonist, on the urinary bladder in rats with spinal cord injury.
    Kadekawa K; Sugaya K; Nishijima S; Ashitomi K; Miyazato M; Ueda T; Yamamoto H
    Life Sci; 2013 May; 92(20-21):1024-8. PubMed ID: 23583569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis, and pharmacological evaluation of piperidin-4-yl amino aryl sulfonamides: novel, potent, selective, orally active, and brain penetrant 5-HT₆ receptor antagonists.
    Nirogi R; Shinde A; Daulatabad A; Kambhampati R; Gudla P; Shaik M; Gampa M; Balasubramaniam S; Gangadasari P; Reballi V; Badange R; Bojja K; Subramanian R; Bhyrapuneni G; Muddana N; Jayarajan P
    J Med Chem; 2012 Nov; 55(21):9255-69. PubMed ID: 23006002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.